Table 1 Demographic characteristics and health metrics
From: Health Disparities among adults cared for at an urban cystic fibrosis program
Non-Hispanic Caucasian (n = 223) | Black/LatinX (n = 39) | p | |
|---|---|---|---|
Female (n, %) | 125 (56.1%) | 17 (43.6%) | 0.149 |
Mean current age *(standard deviation SD) | 35.9 (13.3)) | 32.1 (9.3) | 0.087 |
Mean age at diagnosis, years * | 9.56 (15.9) | 11.59 (15.8) | 0.46 |
Mean sweat chloride * | 92.9 (4.5) | 90.4 (1.7) | 0.87 |
Mean FEV1 L * | 3.01 (7.08) | 2.19L (1.07) | 0.47 |
Mean FEV1 (%) * | 70.6 (22.5) | 59.5 (27.92) | 0.010 |
Mean FVC L * | 3.68 (1.13) | 3.15 (1.19) | 0.008 |
Mean FVC (% predicted) * | 84.17 (18.46) | 73.00 (24.69) | 0.002 |
FEV1/FVC * | 0.77 (1.34) | 0.67 (0.15) | 0.65 |
Mean BMI * | 23.02 (4.09) | 22.44 (4.20) | 0.446 |
Diabetes (n, %) | 56 (25.1) | 14 (35.9) | 0.160 |
Pseudomonas aeruginosa (n, %) | 138 (62) | 25 (64) | 0.67 |
Mean no. encounters | 4.64 (0.17) | 4.4 (0.38) | 0.96 |
Mean no. Intravenous antibiotic (IV) courses * | 0.68 (0.07) | 0.74 (0.22) | 0.67 |
Hospitalizations * | 0.27 (0.05) | 0.86 (0.15) | 0.14 |
Days treated with IV antibiotics * | 11.5 (1.3) | 12.23 (3.9) | 0.92 |
Median income * | 102,494 (36,060) | 68,485 (33,159) | < 0.001 |
Medicaid (n, %) | 18 (8.7%) | 17 (45.9%) | < 0.001 |
Medicaid/Medicare (n, %) | 39 (17.5%) | 19 (48.7%) | < 0.001 |
Treated with modulators (n, %) in 2019 | 116 (52%) | 13 (38%) | 0.78 |
Eligible for elexacaftor/tezacaftor/ivacaftor | 170 (76%) | 24 (62%) | 0.87 |